Professor, Surgery, University of Pittsburgh School of Medicine
General Surgery
Dr. Michael T. Lotze, MD
|
|
Give Review
Dr. Michael T. Lotze is an expert in the field of General Surgery. He went to Northwestern University Feinberg School of Medicine. Northwestern University Feinberg School of Medicine is ranked 19/29 in Research/PrimaryCare. He received awards:"Fellow (FACS)". Michael Lotze is a published physician. He has 100 papers published. The most current publication "Nuclear DAMP complex-mediated RAGE-dependent macrophage celldeath."
Publications
- Nuclear DAMP complex-mediated RAGE-dependent macrophage cell death.
- Classification of current anticancer immunotherapies.
- You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia.
- DAMPs, ageing, and cancer: The 'DAMP Hypothesis'
- HMGB1 in health and disease.
- HMGB1 Phenotypic Role Revealed with Stress.
- Good things come in small packages: exosomes, immunity and cancer.
- Intracellular Hmgb1 Inhibits Inflammatory Nucleosome Release and Limits Acute Pancreatitis in Mice.
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
- HMGB1 in Cancer: Good, Bad, or Both?
- Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer.
- HMGB1: The Central Cytokine for All Lymphoid Cells.
- Signaling of High Mobility Group Box 1 (HMGB1) through Toll-like Receptor 4 in Macrophages Requires CD14.
- DAMPs and autophagy: Cellular adaptation to injury and unscheduled cell death.
- The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells.
- Life after death: targeting high mobility group box 1 in emergent cancer therapies.
- The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics.
- Autophagy is Required for IL-2-Mediated Fibroblast Growth.
- A Janus Tale of Two Active HMGB1 Redox States.
- Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity.
- Damage Associated Molecular Pattern Molecule-Induced microRNAs (DAMPmiRs) in Human Peripheral Blood Mononuclear Cells.
- Cell-mediated autophagy promotes cancer cell survival.
- AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway.
- Inhibiting Systemic Autophagy during Interleukin 2 Immunotherapy Promotes Long-term Tumor Regression.
- Direct molecular interactions between HMGB1 and TP53 in colorectal cancer.
- High mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases.
- Defining the Critical Hurdles in Cancer Immunotherapy.
- Pancreatic Cancer Is Not Noble.
- HMGB1 as an autophagy sensor in oxidative stress.
- High-mobility group box 1 is essential for mitochondrial quality control.
- The Receptor for Advanced Glycation End-Products (RAGE) Protects Pancreatic Tumor Cells Against Oxidative Injury.
- High-mobility group box 1, oxidative stress, and disease.
- RAGE regulates autophagy and apoptosis following oxidative injury.
- Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells.
- High mobility group box 1 (HMGB1) Activates an Autophagic Response to Oxidative Stress.
- Principles and current strategies for targeting autophagy for cancer treatment.
- Endogenous HMGB1 regulates autophagy.
- Meeting report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Oh...
- Cytokine Binding by Polysaccharide-Antibody Conjugates.
- Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation.
- Cancer and inflammation: promise for biologic therapy.
- Biological activities of cytokine-neutralizing hyaluronic acid-antibody conjugates.
- Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function.
- Pharmacologic administration of interleukin-2.
- Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells.
- Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis.
- Low-dose cisplatin administration in murine cecal ligation and puncture prevents the systemic release of HMGB1 and attenuates lethality.
- Ethyl pyruvate administration inhibits hepatic tumor growth.
- Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1.
- The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma.
- Immunotherapy for cancer: promoting innate immunity.
- A nexus of science and clinical immunology: the Federation of Clinical Immunology Societies and the FOCIS Centers of Excellence.
- Focus on FOCIS: interleukin 2 treatment associated autoimmunity.
- Eosinophils induce DC maturation, regulating immunity.
- Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate.
- Systemic inflammation and remote organ injury following trauma require HMGB1.
- Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.
- High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
- Interleukin-12: biological properties and clinical application.
- Damage associated molecular pattern molecules.
- Masquerader: high mobility group box-1 and cancer.
- Cytolytic cells induce HMGB1 release from melanoma cell lines.
- Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury.
- Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors.
- High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists.
- In vivo expansion of two distinct dendritic cells in mouse livers and its impact on liver immune regulation.
- Rapid flow cytometric measurement of cytokine-induced phosphorylation pathways [CIPP] in human peripheral blood leukocytes.
- Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury.
- Pediatric cancers are infiltrated predominantly by macrophages and contain a paucity of dendritic cells: a major nosologic difference with adult tumors.
- Mechanistic insights into achievement of cardiac allograft long-term survival by treatment with immature dendritic cells and sub-dose sirolimus.
- Evidence of the capability of the CMV enhancer to activate in trans gene expression in mammalian cells.
- Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells.
- IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.
- The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.
- The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion.
- Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health.
- Addicted to death: invasive cancer and the immune response to unscheduled cell death.
- A basis for distinguishing cultured dendritic cells and macrophages in cytospins and fixed sections.
- Dying dangerously: Necrotic cell death and chronic inflammation promote tumor growth.
- C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells.
- Differential effects of IL-12 on the generation of alloreactive CTL mediated by murine and human dendritic cells: a critical role for nitric oxide.
- Combined treatment with interleukin-18 and low-dose interleukin-2 induced regression of a murine sarcoma and memory response.
- Interleukin-17 promotes angiogenesis and tumor growth.
- Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
- Natural killer, but not natural killer T, cells play a necessary role in the promotion of an innate antitumor response induced by IL-18.
- Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity.
- Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice.
- Murine dendritic cell-induced tumor apoptosis is partially mediated by nitric oxide.
- Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production.
- High-dose recombinant interleukin-18 induces an effective Th1 immune response to murine MOPC-315 plasmacytoma.
- Interleukin-18 as a novel, distinct, and distant member of the interleukin-1 family promoting development of the adaptive immune response: the interleukin-18 issue of ...
- Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses.
- TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer.
- Paucity of dendritic cells in pancreatic cancer.
- PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis.
- Recombinant Human Interferon Alpha 2b Prevents and Reverses Experimental Pulmonary Hypertension.
- Clearance kinetics and matrix binding partners of the receptor for advanced glycation end products.
- Strange attractors: DAMPs and autophagy link tumor cell death and immunity.
- Targeting Damage-Associated Molecular Pattern Molecules (DAMPs) and DAMP Receptors in Melanoma.
Schools
Northwestern Center Feinberg School of Medicine
Doctors Specialties
- General Surgery
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Great West Healthcare-Cigna PPO
- Coventry Health America PPO
- First Health (Coventry Health Care) PPO
- Community Blue PPO
- Choice Care PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- UPMC PPO
Awards
- Fellow (FACS)
Education
-
University of Rochester -
Northwestern University Feinberg School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Georges E. Al-Khoury, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stefan Scholz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lee Ann Peluso, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard L. Simmons, MD |
|
|
Dr. Ulka Sachdev-Ost II, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hiroshi Sogawa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Herbert J. Zeh III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul D. Bianculli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles F. Cobb, MD |
|
|
Dr. Marigdalia K. Ramirez-Fort, MD |
|
|
Dr. Jose G. Oliva III, MD |
|
|
Dr. Sean P. Whelan, MD |